Wait for Bharat's COVID-19 vaccine data continues
India's Bharat Biotech has recently completed the Phase III trials of its COVID-19 intranasal vaccine BBV154 and submitted the data to the Drug Controller General of India (DCGI) for approval both as a primary two-dose vaccine, and a heterologous booster dose. However, the company has not yet made clinical trial results publicly available.
View the full story here: https://www.thepharmaletter.com/article/clinical-data-disclosure-critical-for-bharat-biotech-covid-19-intranasal-vaccine-success-in-india-says-globaldata